Victory Capital Management
FOLD

Victory Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Victory Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$513K Sell
35,447
-311,981
-90% -$4.47M ﹤0.01% 2029
2025
Q4 		$4.95M Buy
347,428
+4,580
+1% +$45K ﹤0.01% 1319
2025
Q3 		$2.7M Buy
342,848
+239,367
+231% +$1.7M ﹤0.01% 1528
2025
Q2 		$593K Sell
103,481
-153,607
-60% -$991K ﹤0.01% 2023
2025
Q1 		$2.1M Buy
257,088
+82,691
+47% +$765K ﹤0.01% 1515
2024
Q4 		$1.64M Sell
174,397
-1,083,811
-86% -$11.3M ﹤0.01% 1580
2024
Q3 		$13.4M Sell
1,258,208
-1,015,751
-45% -$11.1M 0.01% 995
2024
Q2 		$22.6M Buy
2,273,959
+345,117
+18% +$3.54M 0.02% 761
2024
Q1 		$22.7M Buy
1,928,842
+176,155
+10% +$2.25M 0.02% 769
2023
Q4 		$24.9M Sell
1,752,687
-1,196,519
-41% -$13.6M 0.03% 689
2023
Q3 		$35.9M Buy
2,949,206
+2,350,262
+392% +$30.3M 0.04% 528
2023
Q2 		$7.52M Sell
598,944
-1,311,824
-69% -$15.6M 0.01% 1126
2023
Q1 		$21.2M Buy
1,910,768
+1,728,159
+946% +$21.3M 0.02% 762
2022
Q4 		$2.23M Buy
182,609
+40,875
+29% +$460K ﹤0.01% 1397
2022
Q3 		$1.48M Buy
141,734
+54,584
+63% +$608K ﹤0.01% 1551
2022
Q2 		$936K Buy
87,150
+53,882
+162% +$444K ﹤0.01% 1778
2022
Q1 		$236K Sell
33,268
-780
-2% -$7.31K ﹤0.01% 2374
2021
Q4 		$393K Buy
34,048
+63
+0.2% +$702 ﹤0.01% 2287
2021
Q3 		$325K Sell
33,985
-1,232
-3% -$12.6K ﹤0.01% 2361
2021
Q2 		$339K Buy
35,217
+78
+0.2% +$761 ﹤0.01% 2374
2021
Q1 		$347K Sell
35,139
-3,154,913
-99% -$48.8M ﹤0.01% 2355
2020
Q4 		$73.7M Sell
3,190,052
-635,449
-17% -$13M 0.08% 368
2020
Q3 		$54M Buy
3,825,501
+317,779
+9% +$4.63M 0.07% 441
2020
Q2 		$52.9M Sell
3,507,722
-4,503,246
-56% -$54.9M 0.07% 409
2020
Q1 		$74M Buy
8,010,968
+3,987,792
+99% +$37.9M 0.06% 450
2019
Q4 		$39.2M Buy
4,023,176
+355,292
+10% +$3.25M 0.05% 576
2019
Q3 		$29.4M Buy
3,667,884
+15,425
+0.4% +$167K 0.04% 651
2019
Q2 		$45.6M Buy
3,652,459
+548,730
+18% +$6.96M 0.09% 345
2019
Q1 		$42.2M Sell
3,103,729
-45,120
-1% -$551K 0.1% 332
2018
Q4 		$30.2M Sell
3,148,849
-592,805
-16% -$6.52M 0.08% 424
2018
Q3 		$45.2M Buy
3,741,654
+135,615
+4% +$1.9M 0.09% 365
2018
Q2 		$56.3M Buy
3,606,039
+550,740
+18% +$8.33M 0.12% 256
2018
Q1 		$46M Buy
3,055,299
+410,375
+16% +$6.25M 0.1% 326
2017
Q4 		$38.1M Buy
2,644,924
+151,755
+6% +$2.08M 0.08% 395
2017
Q3 		$37.6M Sell
2,493,169
-1,876,410
-43% -$24.8M 0.08% 378
2017
Q2 		$44M Sell
4,369,579
-589,140
-12% -$4.74M 0.1% 329
2017
Q1 		$35.4M Buy
4,958,719
+883,066
+22% +$5.58M 0.08% 406
2016
Q4 		$20.3M Buy
4,075,653
+55,370
+1% +$383K 0.05% 567
2016
Q3 		$29.8M Buy
+4,020,283
New +$27.2M 0.08% 427

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Victory Capital Management's FOLD Position: Q1 2026 in Review

Victory Capital Management reduced its Amicus Therapeutics (FOLD) stake by 90% in Q1 2026, selling an estimated $4.47M and leaving 35,447 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Victory Capital Management first reported a position in FOLD in Q3 2016 and has held it in 39 quarters since. The position peaked at $74M in Q1 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Victory Capital Management held 35,447 shares of Amicus Therapeutics worth $513K as of Q1 2026.
  • Victory Capital Management sold 311,981 Amicus Therapeutics shares in Q1 2026, an estimated $4.47M.
  • Amicus Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2029 holding.
  • Victory Capital Management first reported a position in Amicus Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • Victory Capital Management's Amicus Therapeutics position peaked at $74M in Q1 2020.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.